Literature DB >> 12023936

Arginine to lysine 108 substitution in recombinant CYP1A2 abolishes methoxyresorufin metabolism in lymphoblastoid cells.

Nicholas E Hadjokas1, Renke Dai, Fred K Friedman, Michael J Spence, Barry J Cusack, Robert E Vestal, Yongsheng Ma.   

Abstract

1. Cytochrome P4501A2 (CYP1A2) activates a large number of procarcinogens to carcinogens. Phytochemicals such as flavones can inhibit CYP1A2 activity competitively, and hydroxylated derivatives of flavone (galangin) may be potent, selective inhibitors of CYP1A2 activity relative to CYP1A1 activity. Molecular modelling of the CYP1A2 interaction with hydroxylated derivatives of flavone suggests that a number of hydrophobic residues of the substrate-binding domain engage in hydrogen bonding with such inhibitors. 2. We have tested this model using site-directed mutagenesis of these residues in expression plasmids transfected into the human B-lymphoblastoid cell line, AHH-1 TK+/-. 3. Consistent with the molecular model's predicted placement in the active site, amino acid substitutions at the predicted residues abolished CYP1A2 enzymatic activity. 4. Transfected cell lines contained equal amounts of immunoreactive CYP1A2. 5. Our results support the molecular model's prediction of the critical amino acid residues present in the hydrophobic active site, residues that can hydrogen bond with CYP1A2 inhibitors and modify substrate binding and/or turnover.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12023936      PMCID: PMC1573356          DOI: 10.1038/sj.bjp.0704711

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  24 in total

Review 1.  Cytochrome P-450. Multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms.

Authors:  T D Porter; M J Coon
Journal:  J Biol Chem       Date:  1991-07-25       Impact factor: 5.157

Review 2.  Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes.

Authors:  F P Guengerich; T Shimada
Journal:  Chem Res Toxicol       Date:  1991 Jul-Aug       Impact factor: 3.739

Review 3.  Cytochrome P450: molecular architecture, mechanism, and prospects for rational inhibitor design.

Authors:  T L Poulos
Journal:  Pharm Res       Date:  1988-02       Impact factor: 4.200

4.  High-resolution crystal structure of cytochrome P450cam.

Authors:  T L Poulos; B C Finzel; A J Howard
Journal:  J Mol Biol       Date:  1987-06-05       Impact factor: 5.469

Review 5.  P-450 cytochromes: structure and function.

Authors:  S D Black; M J Coon
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1987

Review 6.  Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy.

Authors:  F P Guengerich
Journal:  Cancer Res       Date:  1988-06-01       Impact factor: 12.701

7.  Xenobiotic metabolism and mutation in a human lymphoblastoid cell line.

Authors:  C L Crespi; J D Altman; M A Marletta
Journal:  Chem Biol Interact       Date:  1985-05       Impact factor: 5.192

8.  Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450.

Authors:  M D Burke; S Thompson; C R Elcombe; J Halpert; T Haaparanta; R T Mayer
Journal:  Biochem Pharmacol       Date:  1985-09-15       Impact factor: 5.858

9.  Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro.

Authors:  U Fuhr; E M Anders; G Mahr; F Sörgel; A H Staib
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

10.  Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity.

Authors:  P A Williams; J Cosme; V Sridhar; E F Johnson; D E McRee
Journal:  Mol Cell       Date:  2000-01       Impact factor: 17.970

View more
  1 in total

Review 1.  Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2.

Authors:  Shu-Feng Zhou; Li-Ping Yang; Zhi-Wei Zhou; Ya-He Liu; Eli Chan
Journal:  AAPS J       Date:  2009-07-10       Impact factor: 4.009

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.